产品中心
当前位置：首页>产品中心Anti-phospho-BAD(Ser91)/PE-Cy7
货号： bs-12567R-PE-Cy7 基本售价： 2980.0 元 规格： 100ul
产品信息
- 产品编号
- bs-12567R-PE-Cy7
- 英文名称
- Anti-phospho-BAD(Ser91)/PE-Cy7
- 中文名称
- PE-Cy7标记的磷酸化相关死亡促进因子抗体
- 别 名
- Bad (phospho S91); p-Bad (phospho S91); BBC 2; BBC2; BBC6; Bcl 2 Antagonist of Cell Death; Bcl 2 Binding Component 6; BCL X / BCL 2 Binding Protein; BCL X Binding Protein; Bcl XL/Bcl 2 Associated Death Promoter; Bcl-2-like protein 8; Bcl2 antagonist of cell death; BCL2 antagonist of cell death protein; BCL2 associated agonist of cell death; Bcl2 Associated Death Promoter; BCL2 binding component 6; BCL2 binding protein; Bcl2 Like 8 Protein; Bcl2-L-8; BCL2L8; BclXL; Proapoptotic BH3 Only Protein.
- 规格价格
- 100ul/2980元购买 大包装/询价
- 说 明 书
- 100ul
- 产品类型
- 磷酸化抗体
- 研究领域
- 肿瘤 细胞生物 细胞凋亡 新陈代谢
- 抗体来源
- Rabbit
- 克隆类型
- Polyclonal
- 交叉反应
- Human,
- 产品应用
- ICC=1:50-200 IF=1:50-200
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
- 分 子 量
- 18kDa
- 性 状
- Lyophilized or Liquid
- 浓 度
- 1mg/ml
- 免 疫 原
- KLH conjugated synthesised phosphopeptide derived from human BAD around the phosphorylation site of Ser91
- 亚 型
- IgG
- 纯化方法
- affinity purified by Protein A
- 储 存 液
- 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
- 保存条件
- Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
- 产品介绍
- background:
Bad is a member of the Bcl2 family and acts to promote apoptosis by forming heterodimers with the survival proteins Bcl2 and BclxL, thus preventing them from binding with BAX. Bad is found on the outer mitochondrial membrane and, once phosphorylated in response to growth stimuli, translocates to the cytoplasm. The phosphorylation status of Bad represents a key checkpoint for death or cell survival. JNK-induced phosphorylation of BAD serine 128 promotes the apoptotic role of Bad by opposing the inhibitory effect of growth factor on Bad-mediated apoptosis. Cdc2-induced phosphorylation of Bad serine 128 has an inhibitory effect on its interaction with 14-3-3 proteins. The latter interaction is critical for Bad phosphorylation at serine 155, a site within the BH3 domain that leads to the release of BclxL and the promotion of cell survival. Alternative splicing of this gene results in two transcript variants which encode the same isoform.This antibody recognise the phosphorylation site of human Ser75, mouse Ser111, rat Ser112.
Function:
Promotes cell death. Successfully competes for the binding to Bcl-X(L), Bcl-2 and Bcl-W, thereby affecting the level of heterodimerization of these proteins with BAX. Can reverse the death repressor activity of Bcl-X(L), but not that of Bcl-2 (By similarity). Appears to act as a link between growth factor receptor signaling and the apoptotic pathways.
Subcellular Location:
Mitochondrion outer membrane. Cytoplasm. Upon phosphorylation, locates to the cytoplasm.
Tissue Specificity:
Expressed in a wide variety of tissues.
Post-translational modifications:
Phosphorylated on one or more of Ser-75, Ser-99, Ser-118 and Ser-134 in response to survival stimuli, which blocks its pro-apoptotic activity.
Phosphorylation on Ser-99 or Ser-75 promotes heterodimerization with 14-3-3 proteins. This interaction then facilitates the phosphorylation at Ser-118, a site within the BH3 motif, leading to the release of Bcl-X(L) and the promotion of cell survival. Ser-99 is the major site of AKT/PKB phosphorylation, Ser-118 the major site of protein kinase A (CAPK) phosphorylation. Ser-75 is phosphorylated by AKT/PKB, protein kinase A and PIM2.
Similarity:
Belongs to the Bcl-2 family.
Database links:Entrez Gene: 572 Human
Omim: 603167 Human
SwissProt: Q92934 Human
Unigene: 370254 Human
Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.